Core Viewpoint - The article discusses the investigation into a hospital in Shijiazhuang for allegedly selling a traditional Chinese medicine for insomnia that contains the controlled substance diazepam, raising concerns about drug safety and regulatory compliance [1]. Group 1: Investigation and Regulatory Response - The Shijiazhuang Qiaoxi District Market Supervision Administration has initiated an investigation into the Hebei Puzhe Medical and Health Service Co., Ltd. for the alleged addition of sleeping pills in their herbal medicine [1]. - The administration emphasizes its commitment to enhancing drug safety supervision to protect public health [1]. Group 2: Allegations and Consumer Reports - A consumer reported that after purchasing a herbal remedy for insomnia from the hospital, they experienced drowsiness, leading to tests that confirmed the presence of diazepam [1]. - Diazepam is classified as a second-class controlled substance under the Regulations on the Administration of Psychotropic Substances, with risks of dependency and addiction associated with long-term or excessive use [1]. Group 3: Hospital's Response - The on-duty doctor at Puzhe Hospital denied the allegations of adding diazepam to their products when approached by reporters [1].

Core Viewpoint - A listed company in Shenzhen faced a significant operational impact due to its subsidiary's non-compliance with GMP standards, leading to a production and sales suspension, which resulted in a stock price drop to the daily limit [1] Group 1: Company Impact - The subsidiary generated revenue of 216.57 million yuan and a net loss of 14.00 million yuan in 2024, accounting for 60.09% of the listed company's revenue and 9.8% of its consolidated net profit, indicating a substantial impact on the parent company's operations [1] - The company may face other risk warnings if the subsidiary's production does not resume within three months, as per the Shenzhen Stock Exchange's regulations [1] Group 2: Social Responsibility - Companies in the pharmaceutical sector must prioritize social responsibility and product safety, as the quality of drugs directly affects public health [2] - The concept of "pharmaceutical ethics" should guide the operations of pharmaceutical companies, balancing profit maximization with stakeholder interests [2] Group 3: Recommendations for Improvement - It is recommended that pharmaceutical companies innovate their internal governance by establishing independent quality control committees to oversee production processes and ensure compliance with GMP standards [2] - Companies should enhance their social responsibility disclosures, especially in cases of significant incidents or regulatory actions, to maintain transparency and accountability [3] - The trading rules should be revised to provide clearer criteria for implementing risk warnings, ensuring that the exchange, rather than the company, determines the necessity for such warnings [3] Group 4: Conclusion - Pharmaceutical companies must embed the principle of "quality is life" into their governance structures and operational practices to succeed in both capital markets and public health demands [4]

维护老字号品牌声誉 4名非法生产、销售安宫牛黄 丸的同仁堂"内鬼"均获刑 在分析该案的典型意义时，刘杰表示，安宫牛黄丸属于以危重病人为主要使用对象的急救药品。根 据"两高"药品安全司法解释的相关规定，未取得药品相关批准证明文件生产药品或者明知是上述药品而 销售，涉案药品属于以孕妇、儿童或者危重病人为主要使用对象的，应当认定为"足以严重危害人体健 康"。王某1等人虽系同仁堂制药厂员工，但私自生产安宫牛黄丸并销售属于未经批准生产、销售危重病 人为主要使用对象的急救药，可以认定其行为已达到足以严重危害人体健康程度，即使没有药品使用者 造成实质性危害后果，也构成犯罪。私自生产药品，不仅危及公众健康，还破坏了企业声誉、挤压了企 业竞争空间。 "本案依法打击私自制售安宫牛黄丸的同仁堂"内鬼"，不仅保护了公众用药安全，同时为老字号企业营 造了公平的市场环境，维护了老字号品牌声誉及价值。"刘杰说。 来源：中国青年报客户端 中国青年报客户端北京3月25日电（中青报·中青网记者 何春中）今天，北京市朝阳区人民法院（以下简 称朝阳法院）召开新闻通报会，通报了该院依法打击非法生产、销售安宫牛黄丸的同仁堂"内鬼"，维护 老字号品牌声誉 ...